期刊文献+

热疗联合化疗对晚期卵巢癌患者凝血指标的影响及临床分析 被引量:2

Effect of hyperthermia combined with chemotherapy on coagulation index of advanced ovarian cancer patients and its clinical analysis
原文传递
导出
摘要 目的探讨热疗联合化疗治疗晚期卵巢癌,观察其对凝血指标的影响及临床分析。方法选取2016年11月—2018年11月于郑州大学第一附属医院肿瘤科治疗的88例晚期卵巢癌患者,根据治疗方案不同分为观察组41例与对照组47例,观察组采用热疗联合化疗,对照组采用单纯化疗,两组均连续治疗2个周期,比较两组患者治疗前后的凝血指标。结果观察组治疗后纤维蛋白原(FIB)、D-二聚体(D-D)、凝血酶时间(TT)均低于治疗前,差异有统计学意义(P<0.05),凝血酶原时间(PT)、部分活化凝血活酶时间(APTT)治疗后较治疗前有改善,但差异无统计学意义(P>0.05)。观察组治疗后的D-D、FIB、TT较治疗前的改善情况优于对照组,差异有统计学意义(P<0.05)。结论热疗联合化疗治疗晚期卵巢癌可降低D-D、Fib、TT水平,调节凝血纤溶平衡,降低患者高凝状态,一定程度上降低卵巢癌的转移和侵袭风险,建议临床推广实施。 Objective To investigate the effect of hyperthermia combined with chemotherapy on coagulation in advanced ovarian cancer and its clinical analysis.Methods Totally 88 patients with advanced ovarian cancer treated in oncology department of the First Affiliated Hospital of Zhengzhou University from November 2016 to November 2018 were enrolled.According to the treatment plan,41 patients in the control group and 47 patients in the observation group were selected.The observation group was treated with hyperthermia combined with chemotherapy.The control group received chemotherapy alone.Both groups were treated continuously for 2 cycles,Blood coagulation indexes before and after treatment were compared between the two groups.Results After treatment, fibrinogen(FIB), D-dimer(D-D) and thrombin time(TT) in the observation group were all lower than before treatment.The difference was significant(P<0.05).Prothrombin time(PT) and partially activated thrombin time(APTT) were improved after treatment compared with before treatment.But the difference was not significant(P>0.05).The improvement of d-d, FIB and TT in the observation group was better than that in the control group after treatment, and the difference was significant(P<0.05).Conclusion Hyperthermia combined with chemotherapy for advanced ovarian cancer can reduce the levels of D-D, FIB and TT,regulate coagulation and fibrinolysis balance,reduce the patient’s hypercoagulability,to reduce the risk of metastasis and invasion of ovarian cancer.It is suggested to carry out clinical extension.
作者 李梦华 都小晗 吴风莲 王映 路太英 LI Meng-hua;DU Xiao-han;WU Feng-lian;WANG Ying;LU Tai-ying(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处 《医药论坛杂志》 2020年第10期41-43,48,共4页 Journal of Medical Forum
关键词 深部热疗 卵巢癌 D-二聚体 凝血指标 Hyperthermia Ovarian cancer D-dimer Coagulation indicators
  • 相关文献

参考文献5

二级参考文献62

  • 1王明山,杨丽红,潘景业,王霄霞,陆红,吕美艳,陈少贤,谢于鹏.晚期肺癌患者化疗过程中抗凝血酶和纤溶功能的变化及意义[J].中国肺癌杂志,2007,10(3):226-228. 被引量:13
  • 2胡元晶,曲芃芃.卵巢癌化疗的最新进展[J].国外医学(妇产科学分册),2005,32(2):122-124. 被引量:10
  • 3Weitz LC, Israel VK, Waisman JR, et al. Chemotherapy-induced activation of hemostasis : effect of a low molecular weight heparin ( daheparin sodium) on plasma markers of hemostatic activation[ J].Thromb Haemost,2002,88 (2) :213.
  • 4R Cool, J Herringon, L Wong. Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide [ J]. Pharmacotherapy, 2002,22 (9) :1200.
  • 5G Togna, A Togna, M Franconi, et al. Cisplatin triggers platelet activation [ J]. Thromb Res,2000,99 (5) :503.
  • 6Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy[ J]. Thromb Haemostasis, 1997,78 ( 1 ) : 133.
  • 7Edoute Y, Haim N, Rinkevich D, et al. Cardiac valvlar vegetations in cancer patients : aprospective echocardio-graphic study of 200 patients [J]. AM J Med,1997,102(3) :252.
  • 8Daly MB, Ozols RF. Symptoms of ovarian cancer-Where to set the bar[J].JAMA, 2004, 291 (22):2755-2756.
  • 9Harter P, du Bois A. The role of surgery in ovarian cancer with spe- cial emphasis on cytoreductive surgery for recurrence[J]. Curr Opin Oncol. 2005. 17:505-514.
  • 10Ferrandina G, Legge F, Salutari V, et al. Impact of pattern of recur- rence on clixfical outcome of ovarian cancer patients: clinical consid- erations[J]. EurJ Cancer, 2006, 42:2296-2302.

共引文献136

同被引文献23

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部